All In Biotech

Drug Trial Radar · NCT07949695

Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer

An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

May 31, 2028

Study completion May 31, 2029

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer. Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety. A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.

Conditions

  • HR Positive/HER2 Low Breast Cancer
  • Neoadjuvant Therapy
  • SHR-A1811
  • Toripalimab

Interventions

  • trastuzumab rezetecan (SHR-A1811) Toripalima、Endocrine therapy(ET)Drug

    Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response Rate (pCR, ypT0/isN0)Time frame: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.